Semaglutide is the most-searched name in the GLP-1 space, so a lot of people looking into metabolic research start there. Here's where it actually sits among the research peptides — and the compounds Australian researchers increasingly study instead.
What Semaglutide is
Semaglutide is a single-receptor GLP-1 agonist — it engages one incretin pathway. It's the reference compound most newer molecules get compared against, which is exactly why it's the name everyone searches first.
Why researchers move to dual and triple agonists
The active research question is what happens when you engage more than one receptor pathway. That's led to two compounds getting a lot of attention:
- Tirzepatide — a dual agonist (GLP-1 + GIP).
- Retatrutide — a triple agonist (GLP-1 + GIP + glucagon).
Think of it as a ladder: Semaglutide (single) → Tirzepatide (dual) → Retatrutide (triple). Our Retatrutide vs Semaglutide and Semaglutide vs Tirzepatide vs Retatrutide pieces compare them side by side.
What we stock in Australia
We don't currently stock Semaglutide — but we hold both compounds researchers most often compare it to, in Australian stock:
- Retatrutide — 10MG and 20MG
- Tirzepatide — 20MG
Both are independently batch-tested with a published Certificate of Analysis in our CoA Library, dispatched same or next business day from Melbourne.
Buying metabolic research peptides in Australia
If you're comparing suppliers, our buy peptides Australia page covers what to check (published CoAs, local stock, secure payment). For the science first, start with the GLP-1 research landscape.
Shop metabolic research peptides →
All products are supplied strictly for laboratory and in-vitro research use only. Not for human or veterinary consumption. This article describes fields of scientific research and is not medical advice or a claim about effects in humans.